Mistletoe therapy
Patient information
Dear reader
With many forms of cancer it is nowadays possible to achieve a lasting
cure. Nevertheless, however positive this statement may be, the diagnosis
of "cancer" is justifiably always associated with many questions and anxieties
for the patient, his family and circle of friends. This brochure is intended
to help encourage discussions between doctor, patient, family and
friends, to answer unresolved questions, and to stimulate an informed approach
to the disease. We would be happy if reading this brochure encourages
you to adopt an active approach to your cancer, for this is a de-
finite step towards successful therapy.
The staff at
ABNOBA Heilmittel GmbH
Apple tree, host to apple mistletoe (Viscum album, Mali)
What is cancer?
Historically, cancer has been detectable from the earliest times. However,
the frequency and nature of the disease have changed with the different
civilisations. Today, for example, tumour diseases of the bowel are
increasing because of changes in dietary habits.
The question "What is cancer?" used to be answered on the basis of externally
visible symptoms, but today molecular biological and genetic explanations
have taken precedence.
The terms "tumour", "cancer", "leukaemia" and many other names cover
more than a hundred different diseases which have in common the uncontrolled
and malignant growth of body cells. All healthy cells follow an ordered life course. The life cycle of malignant
cells and their proliferation by cell division, however, no longer fits in with
the body as a whole and develops an independent "life of its own".
Scientifically, the cause of this lies in the presence, in the diseased cells, of
"disrupted" genes which are responsible for cell growth and function. In
healthy subjects, this genetically ordained programming is also controlled
by the neighbouring cells and by messenger substances in the human blood
so that human organs or tissues assume an appropriate size and form. Each
organ grows or regenerates itself to its natural individual size and shape.
The diseased cell, however, lacks "information" about its function and its
intended location. It therefore invades foreign tissue as well and migrates, establishing itself (metastasising) in other regions of the body. Generally,
the cellular changes occur years before the disease is ever apparent.
However, not only has the individual cell and the enclosing organ- or
tissue-forming architecture lost its capacity for control to the tumour, but
so has the whole body as well. Cancer is therefore always also a disease
of the human immune system. In the human body, new cells are constantly
being formed and old ones dying. This natural process that occurs
daily in millions of different ways is "monitored" by the immune system.
In cancer, the immune system has, among other things, lost the ability to
intercept messenger substances that stimulate the unbridled growth of
cells and to destroy malformed cells.
There are therefore three disorders regularly associated with cancer disease:
the degenerated genetic information in the cell,
the lack of communication between cells which determines the shape
and size of tissues or organs
and the disorientation or weakness of the immune system.
Tumours present as solid and sometimes palpable growths or systemically
in the whole body, for example as a lymphoma or leukaemia. In solid
tumours, the removal of tumour tissue (biopsy) determines how malignant
the tumour is. The more similar the tumour is to the tissue out of
which it is growing, the more likely it will be "graded" as benign (harmless)
because at that stage it has only to a limited extent developed its
own dynamic processes distinct from the rest of the body. In addition to
grading, tumours are also classified in terms of the TNM system which describes
the size of the tumour, the involvement of the lymphatic system
and the spread of metastases. (For "Grading" and "TNM system" see also
the detailed index in the appendix.)
What causes cancer?
An unambiguous and conclusive causal relationship can at present only
be established for certain carcinogenic, i.e. cancer-producing, substances
and radiation. The essential factor here is the quantity of harmful substances
absorbed in relation to the "strength" of the individual defences
or the immune system. In this context, it should be noted that nowadays
more than half of all cancers are related to smoking and alcohol consumption
or to unbalanced dietary habits.
In certain forms of cancer, a hereditary incidence can be observed (e.g.
breast cancer). In this case, it is possible to talk of a latent predisposition
and with it an associated increased risk of disease. What however ultimately
results in the loss of control of genetic information in the cell and
the associated malignant growth cannot yet be answered scientifically.
The attempted explanation so often given previously, that underlying
the disease was a weakened immune system, is no longer tenable in the
current state of knowledge. It is, however, certain that once the disease
has appeared, the immune system no longer recognises the cancer as a
foreign process and therefore fails to fight it, or at least to fight it adequately.
It is therefore important therapeutically to boost the immune system
and to influence it in such a way that it recognises the cancer speci-
fically.
Apart from the mainly psychological addictive habits, such as tobacco
misuse, which frequently precede an illness, no psychological causes have
been demonstrated. Yet it appears that stress, worry or irregular life styles
are sometimes closely related to the disease, or result in the manifestation
of a previously 'dormant' disease. To date, however, no scientifi-
cally conclusive evidence has been found for this. This is due not only to
the complicated nature of the facts, but also to the still young scientific disciplines which study the interaction between psychological and physical
processes, psychosomatics or psycho-oncology. Also, the simple explanation
often advanced that there is a specific cancer type, in other words
a personal predisposition to cancer, has not proved correct in any respect.
These comments, however, should not conceal the fact that there is undoubtedly
a relationship between psychological constitution and physical
process which current scientific methodology are unable to describe adequately.
Self-reproach or the gnawing question of "why me?" are therefore
only beneficial if they do not result in excessive fatalism, but instead in a
change of previous habits. Artistic activities or art therapy can here provide
a very meaningful and successful supplement to medical therapy.
Taking up new interests should also be mentioned in this context.
As a rule, it is the interaction of several factors which is used today to
explain the disease. Each therapy is therefore only rarely limited to one
particular aspect, and should instead take account of and include a wide
range of social, individual, environmental, physical and psychological factors.
An exact description of your condition and your situation will be extremely
useful to your doctor in establishing your individual therapeutic
plan.
Psychological reactions
to the diagnosis
Just the suspicion of cancer unleashes many fears. This applies to the
patient and also, in terms of the uncertainty, to the doctor who, although
he knows what the disease is when it is first detected, does not know its
severity. In spite of this he is expected to provide definite responses from
the outset.
Many patients describe their experience of waiting for the test results,
of the associated uncertainty, of the hopes and fears relating to a lifethreatening
disease, as often being more unbearable than the knowledge
of being ill.
To ensure that wild speculation is not given free rein at a time when so
many different suspicions are circulating, discuss the nature and scope of
the information that is available to you, your family and friends with your
doctor. This can form the basis for intimate and honest discussions for
everyone involved.
The patient often has the feeling "as if the floor had been taken away
from under his feet" if he suspects and then finally knows that he is suffering
from cancer. This experience is described as diagnosis shock and is
an entirely normal reaction to a so extraordinary event. A "healthy" selfconfidence
and the active deployment of all one’s usual resources will not
always be possible in this situation and are only rediscovered with time.
It is only natural that patients under huge psychological stress should experience
rapid changes of mood and a greater debility than they previously
have done. This requires a considerable amount of consideration
and objectivity on the part of family and friends. Objectivity, however,
also includes expressing hopes and wishes clearly and basing them on
truth as far as successful therapy is concerned.
The patient can, however, also tell himself that people close to him
would be happy to help and are also faced with an entirely new situation.
A clear discussion of what is and is not good for him constitutes a good
basis for agreeable help and support.
Many patients want to approach the disease intellectually in order to
make a definite assessment and to provide a healthy corrective to fluctuating
moods. Obtaining information and, through first hand experience,
supporting medical measures on the basis of one's own judgement
can then be a major help for all those involved. It is sometimes necessary
here to seek advice from another doctor or pharmacist. However, you as
a patient can enhance the confidential relationship with your doctor
from the start if you discuss any questions and opinions with him openly,
including "well-meaning" advice from family and friends. If treatment is
to be successful, it is important to back one's own decisions as well as
those made jointly.
Everything that the patient can do to achieve psychological balance
and mental alertness represents the basis for "healthy" control of the disease.
Pine, host tree to pine mistletoe (Viscum album, Pini)
Cancer treatments
In the treatment of cancer the following types of therapy are distinguished
from one another:
Curative therapies, such as surgery and radiotherapy, are intended to
cure the disease.
Adjuvant therapies, i.e. supporting therapies, are intended to support
the success of curative therapy, for example when chemotherapy is started
after surgery to suppress the growth of, or kill, any cells that have
spread.
Palliative therapies result for instance in the relief of tumour pain and
are intended in particular to produce a higher quality of life, such as improved
appetite and deeper sleep in patients. These therapies are often
used in severely ill patients.
Supportive therapies serve to relieve or suppress severe side-effects
that regularly occur with chemotherapy and radiotherapy. For instance,
disorders of the blood-forming function of the bone marrow, nausea and
pain are treated, but also psychosocial disorders in the course of the disease
with the aim of achieving a more effective therapy.
A further distinction is made between local therapies, which combat a
tumour directly by surgery, radiotherapy or the targeted administration
of drugs, and systemic therapies. Systemic therapies have a cytostatic or
hormonal effect and suppress the growth of diseased cells and tissue in
the whole body or, as mistletoe therapy does, stimulate the immune system
in its role against the cancer.
Surgery and radiotherapy
If a tumour can be removed surgically, particularly in the early stages
of disease, this is the most effective treatment of all. To ensure that no affected
tissue remains in the body, a small part of the healthy tissue surrounding
the tumour is always removed at the same time. The surgeon
thus often removes neighbouring lymph nodes because metastatic cells
use the lymphatic system in particular to spread
through the body. With cancer that has already spread, it may be useful
to remove the primary tumour before beginning systemic treatment, i.e.
involving the whole body, in order to then administer effective therapy
with drugs or radiation. Only in the case of rare, slow-growing tumours
are distant metastases also included in surgical therapy.
Surgery is frequently followed by chemotherapy, radiotherapy and/or
hormonal therapy. Radiotherapy is administered either by means of radiation
from the outside (percutaneous therapy) or by implanting radiation-
emitting substances into the body (brachytherapy). Different types
of ionising radiation, e.g. X-rays or gamma rays, are used to destroy the
genetic information (DNA) of cells found in the cell nucleus in such a way
as to cause them to die or to inhibit their growth. Depending on the nature
and size of the tumour, radiation must be given for several treatments
in order to achieve a therapeutically effective total dose. The techniques
used today enable the tumour to be targeted very specifically and
consequently reduce the damage to irradiated, healthy tissue. Side-effects
of this therapy appear after months and even years if healthy cells
are also damaged by the radiation. The symptoms of the side-effects during
and shortly after therapy are very similar to those of chemotherapy.
Mistletoe therapy in support
of surgery and radiotherapy
With radiotherapy and surgery, mistletoe preparations can supplement
and promote treatment both neoadjuvantly, in other words before the
beginning of local therapy, and adjuvantly, i.e. accompanying or supporting
it. Surgery, particularly when associated with anaesthesia, and radiotherapy
expose the whole body to considerable stress. A previous improvement
in the general state of health and immune status with mistletoe
therapy therefore regularly results in improved tolerability of these
therapies, which are intended to work locally only, but have an undermining
effect on the body as a whole.
The granulocytes and macrophages stimulated by mistletoe therapy
and thus occurring to an increased extent in the blood help to produce a
more rapid recovery after radiotherapy or surgery. Granulocytes and
macrophages are white blood cells which remove diseased or dead cells.
The aim of adjuvant Viscum therapy (Viscum is the Latin term for mistletoe)
is to stimulate the body's own defensive system and thus prevent a
recurrence of the tumour, or relapse. This is because an altered or stimulated
immune system can counteract the recurrence of the disease.
In addition, the genetic information (DNA) of healthy cells can be protected
by Viscum during radiotherapy.
In addition, the genetic information (DNA) of healthy cells can be protected
by Viscum during radiotherapy.
Viscum therapy can be started up to two weeks before surgery or earlier
and is then discontinued two days before surgery. Treatment is then
continued if there are no longer any after-effects of the drugs necessary
for surgery and if inflammation-free wound healing is observed. Depending
on the duration of the treatment-free interval, a lower dose of the
mistletoe preparation may need to be used initially.
It is not recommended to begin mistletoe therapy only one week before
surgery as the whole body experiences too great a stress as a result.
Medical therapies
All cancer therapy is supplemented by drugs or administered solely by
drugs. In Germany, chemotherapy, mistletoe therapy and hormonal
therapy are the options most commonly used.
Chemotherapy
Acute leukaemia in children, certain types of testicular cancer, Hodgkin's
disease and many other tumour diseases can today be treated successfully
with the use of chemotherapeutic agents (also known as cytostatics).
Although not as successful as in the examples mentioned above, chemotherapeutic
agents have been developed for almost all cancer diseases.
Most of them exploit the reproductive and metabolic mechanisms
known for cancer cells and healthy cells and their chronological sequence
to produce a growth-inhibiting effect on the formation of new cells.
Tumour cells frequently proliferate by a more rapid cell division than
most healthy cells. The genetic information which is the cause of the rapid
and uninhibited cell division is attacked by chemotherapeutic agents
and thus further tumour growth or the survival of already existing malignant
cells is prevented. A reduction in the size of the tumour or its complete
disappearance can also occur. This is referred to as a partial or complete
remission.
During chemotherapy, in most cases several substances are used to proceed
effectively against the cancer. This "polychemo" combats cell division
with a variety of substances in order to interfere with a wide variety
of mechanisms of cell division, but also to avoid , for example, a one-sided
resistance on the part of the tumour. One typical side-effect of chemotherapy
also derives from the mechanism described above. Mucous
membranes and hair-forming cells are regularly severely affected because
their growth or reproduction is also based on rapid cell division.Slow-growing tumours (e.g. epithelial tumours) therefore, in some cases,
offer chemotherapy fewer points of attack.
The vomiting (Latin: emesis) that is frequently associated with some
drugs used in chemotherapy is treated by anti-emetic medications. The
exact cause of this vomiting is still not sufficiently explained.
The success of a chemotherapy is based not only on the reduction in
size of the tumour but also on the relapse-free period after the end of
therapy. This requires the chemotherapy where possible to reach all the
diseased cells in the body.
The optimal dose is established individually in chemotherapy - as also
in therapy with mistletoe - and is dependent in particular on blood values
which show the functional capacity of the bone marrow. This relates in
particular to leucocytes. The number of leucocytes in the blood is a measure
of the functional capacity of the human immune system.
Chemotherapy is generally administered over several sessions lasting
about a week, known as "cycles" or "courses". All cycles and the treatment-
free intervals introduced after each cycle generally cover a period of
about six months. Detailed information on chemotherapy and hormonal
therapy in cancer which correctly describes the effects and side-effects can
be obtained from the addresses given on page 38.
Hormonal therapy
The growth of sex-specific organs is controlled in healthy human
beings by hormones. In the 1940s, it was recognised that specifically those
tumours which form on or in such organs can be regulated in their growth
by withdrawing hormones. The withdrawal of hormones prevents the
diseased cells from dividing because of the elimination of growth-promoting
signals. It does not act like chemotherapy or radiotherapy by
damaging the genetic material.
The withdrawal of hormones can be done surgically, e.g. by removing
adrenal glands, ovaries or testes, or by medically suppressing female or
male hormone formation. Thus, by administering female hormones, oestrogens,
a successful outcome can be achieved in prostate carcinoma,
and vice versa with gestagens, the artificially manufactured male hormone,
in breast cancer in women. Other methods again suppress the signals
for hormone formation in the pituitary gland and thus the subsequent
formation of hormones in the reproductive glands. Finally, the
"communication pathway" between hormones and cells can be interrupted
by administration of drugs which block or change the cell receptors
necessary for growth signals. Receptors are cell organs for receiving food
and information, e.g. on cell division or cell growth.
Typical side-effects of hormonal therapy are menopausal symptoms in
women and a loss of desire in men and also of potency with some medicines.
Hormonal therapy can last from a few weeks to several years. In unfavourable
cases, however, resistance to hormones can develop in tumour
cells after long-term therapy, so that hormonal therapy is often supplemented
by chemotherapy.
Mistletoe therapy to support
chemotherapy and hormonal therapy
Chemotherapeutic agents damage the body's own formation of leucocytes,
as a result of which the patient is highly susceptible to infection.
Infections, including a harmless cold, can further weaken the body to a
considerably greater extent during chemotherapy and may even result in
the cycle being stopped or in a non-optimal dosage of chemotherapy.
Treatment with mistletoe activates natural killer cells (NK cells), among
others, which belong to the leucocytes, and stimulates their proliferation.
Granulocytes and macrophages, which are also leucocytes and which remove
dead or diseased cells and thus reduce the susceptibility to infections,
are likewise increased. Furthermore the adjuvant (supportive) administration
of mistletoe enables the dose of those drugs intended to
prevent vomiting during chemotherapy to be reduced.
All these effects contribute to a better general state of health. This is
also supported by the release of interleukins. Interleukins increase,
among other things, the production of the body's natural morphines (socalled
endorphins) and lighten the depressed mood often produced by
chemotherapy, therefore increasing acceptance of the therapy. The appetite-
enhancing and mood-lightening effect of mistletoe therapy can in
this way be used to support chemotherapy.
Hormonal therapy effectively suppresses, albeit ‘only’ one-sided, the
hormonally controlled growth of tumour cells. Therapy with mistletoe
can be viewed here as a holistic, supplementary treatment of the ill patient.
The serious attack on the patient’s hormone balance requires the accompanying
immunomodulation described in the beginning of the next
section.
Mistletoe plant in winter, birch, host tree to birch mistletoe (Viscum album, Betulae)
Mistletoe therapy
Therapy with mistletoe products is used in a number of different ways
and for a broad spectrum of tumour diseases. Within a treatment plan, it
can have a supportive (adjuvant), alleviating (palliative) or, most commonly,
a general strengthening and preventive character.
In oncology, attention is devoted principally to the aspects of quality of
life, prolonging survival and relapse prophylaxis. Mistletoe therapy can
be used in a variety of ways for these purposes:
The body's own defences are strengthened by mistletoe therapy in
such a way that granulocytes, lymphocytes and natural killer cells appear
in the blood to an increased extent. Any degenerated cells still
found in the body can therefore be combated and the risk of metastatic
spread reduced.
Mistletoe therapy can therefore improve the immune system weakened
by surgery, anaesthesia, radiotherapy and chemotherapy in its role
against cancer.
A healthy immune system, i.e. one which reacts in a variety of ways,
makes relapses less likely. To this extent, mistletoe therapy is also a preventive
measure in terms of relapse prophylaxis.
Mistletoe therapy can reduce or make more bearable the pain which
can occur in advanced stages of tumours by stimulating the release of
endorphins. Endorphins are natural morphines produced by the body
which have a pain-relieving action.
The loss of appetite and the disturbed sleep pattern that frequently occur
in association with a cancer disease can be eliminated or alleviated.
Healthy eating and sleeping behaviour should not be underestimated
as a precondition for long-term recovery. This also applies to the reduced
susceptibility to infectious diseases that can be observed during
mistletoe therapy.
It has been shown in several studies that mistletoe injections have a
protective effect on the genetic material (DNA) of human cells. This
also explains the improved tolerance of chemotherapy or radiotherapy
during mistletoe therapy.
As well as these effects which are based primarily on immunomodulation,
a cytotoxic effect of Viscum album on tumour cells has also been demonstrated.
Cytotoxic effects, i.e. which destroy cells, are exerted in particular
by the lectins and viscotoxins contained in mistletoe.
Therapeutic effects of the
ingredients of mistletoe
Mistletoe preparations are plant-based medicines, and use the whole
plant or the composition of active substances in the plant as the basis for
their therapeutic effect. However, some manufacturers concentrate their
efforts solely on one ingredient, the lectin content of mistletoe.
In this respect, the widespread belief that plant medicines are harmless
is incorrect, for although the side-effects of therapy with mistletoe preparations
are comparatively minor, some of the individual ingredients are
among the most poisonous substances known. Mistletoe preparations for
this reason can only be obtained on prescription and are not to be used
without medical supervision. The fact that, despite this, the side-effects
that occur are only minor is due to the interaction of the various ingredients in mistletoe. This effect, known as synergy, is however also shown
in a totally different way when laboratory tests on different tumour cells
have shown that individual ingredients of mistletoe, such as lectins, have
a markedly lower therapeutic effect than the extract of the mistletoe
plant as a whole.
Two important groups of substances in mistletoe are viscotoxins and
lectins.
Viscotoxins produce necrosis, in other words they cause cell death by poisoning
the cell, accompanied by inflammation. Lectins, however, act on
the cell nucleus where they cause an apoptotic reaction of the cell.
Apoptosis means the stimulation of an ordered degradation of all the cell
components, comparable to natural cell death. At present, four groups of
mistletoe lectins are known.
In addition to the function described, directed specifically against the
diseased cell, mistletoe possesses the property, as already mentioned, of
having a modulating effect on the immune system. In this way, the immune
system can be stimulated as a whole, non-specifically or specifically,
in its capacity to deal with diseased cells or foreign substances. The nonspecific
reactions, which are inherent in the immune system, include a
marked increase in leucocytes in the blood. Specific reactions, i.e. the immune
system learns this reaction as a result of administration of the drug,
are for example the increased formation of T-cells and B-cells. Mistletoe therapy therefore stimulates the immune system to
"remember" its tidying and cleaning function. This is confirmed by clinical
studies..
Mistletoe therapy may therefore be seen as a meaningful supplement to
conventional therapies.
The normal method of giving the subcutaneous injection is described below and reference is made to the typical side-effects and the readily
observed therapeutic effects.
Practical use
and action
Mistletoe preparations are administered by subcutaneous injection,
i.e. the contents of the ampoules are injected under the skin. As a rule,
this is done two or three times weekly. Only freshly opened ampoules
should be used. The administered dose is increased during the first few
weeks, depending on the state of health and the therapeutic aims. The
increase in dose is intended to achieve the most effective individual dose.
It can however happen that an optimum level is achieved with the very
first dose used. An effective and tolerated dose is readily recognised by
the patient on the basis of the reactions described below. It should be
mentioned first of all however that these reactions or side-effects are
normally a sign that the body is responding to treatment. Side-effects are
therefore to a certain extent therapeutically desirable.
With an adequate dose, redness and/or swelling of up to five centimetres
in diameter will form at the injection site after about six to eight
hours. This local reaction is associated with itching and will persist for not
more than three days. If the local reaction occurs to a lesser extent after
about 2.5 weeks of treatment, a further increase in dose can be undertaken.
This can often result in the local reaction once again having a diameter
of up to five centimetres. The dose is increased once or twice at
the beginning of therapy. After about nine weeks of uninterrupted use
of the same dose, the local reaction will decline and finally disappear
altogether.
The following side-effects may also occur at the beginning of treatment
and be experienced as unpleasant: fatigue, flu-like sensation or dizziness. These reactions appear a few hours after the injection for a maximum
of 24 hours and can be accompanied by a slight fever. Fever is unpleasant,
but is also always a sign of increased positive activity of the immune
system. The daily timetable should always allow for the occurrence
of a slight fever at the beginning of therapy. However, even these sideeffects
have disappeared after the first nine weeks or are only very
slightly apparent.
The doctor will adjust the number of weekly injections and the dose
used according to the severity of these effects. If there are no symptoms
at all, a change in the type of mistletoe, i.e. the host tree on which the
mistletoe has grown, may be considered (e.g. changing from Viscum album
Mali (apple tree mistletoe) to Viscum album Abietis (fir mistletoe).
In the first two weeks of therapy the tendency to slight "chills" that
frequently occurs in cancer patients will decrease and they will experience
a greater feeling of warmth throughout their whole body. In general,
a deeper, more recuperative night's sleep is also obtained and the appetite
will increase. In addition, in many patients a lightening of mood
and an associated feeling of greater well-being and hence increased quality
of life will be observed.
Some doctors place particular emphasis on the fact that the patient’s
body temperature should be measured and recorded in the morning and
evening because the temperature difference can show an immunomodulatory
effect of mistletoe therapy. In patients there is almost always only
a minor difference in temperature, whereas healthy subjects show a marked
difference between morning and evening temperature. This "circadian"
temperature rhythm will in most cases adjust to the natural rhythm
after a few weeks and is also the sign of a response to therapy.
Maple, host tree to maple mistletoe (Viscum album, Aceris)
Duration of therapy,
treatment-free intervals
Mistletoe products are used for a period of two to seven years depending
on the aim of treatment. This period, also known as "maintenance
therapy", is intended for immunomodulation and thus indirectly for the
effective prevention of relapses. Relapses are tumours which recur after
a successful curative treatment (e.g. after surgery). Often there is an interval
of several years between the successful treatment and the occurrence
of a relapse. Preventive (prophylactic) therapies against relapses
are therefore long-term and should be directed at the whole body.
Mistletoe preparations are suitable for effective relapse prophylaxis because
any medication directed solely at the diseased cell would fail to
achieve a long-term improvement in the health of the whole body.
Treatment-free intervals can be introduced during this long-term
maintenance therapy. This is frequently done to restimulate the immune
system to a greater extent by means of different stimuli or because, for
example, additional stress must be avoided during flu. However external
circumstances can also justify a break.
In this context, it should be pointed out that after a break of more than
two months a low dose must again be used to begin with because the
immune system has a learning capacity and once it has "learnt the poisons
of mistletoe" it can respond very violently to a large quantity of
these substances.
Maintenance therapy is programmed according to the individual treatment
plan. In most cases an unchanged dosage is prescribed during this
period. However, different dosages are also used to act rhythmically on
the immune system. In modulating the immune system, it can also be
helpful for the doctor to change the species (see here also the section
"Mistletoe host trees).
If the body has become accustomed to the medication in the course of long-term therapy, a further increase in dose can be undertaken, as at the
beginning of therapy. Towards the end of maintenance therapy injections
are carried out normally only once a week, interspersed by longer
treatment-free intervals.
Manufacture of the medicine
Mistletoe products are manufactured as an extract of mistletoe from
the relevant host trees. Many manufacturers use the mistletoe collected
in both summer and winter, while others only use the plants harvested in
winter. Different extraction procedures and solvents are also used. The
spectra of ingredients and active substances therefore differs in each product
that is on the market.
The Abnoba company uses both summer and winter mistletoe for the
manufacture of the medicinal product in order to ensure a wide spectrum
of ingredients. The mistletoe is then extracted without exposure to air according
to a patented procedure so that as a result more than 75% of the
plant material used is available in the drug. All essential ingredients such
as lectins, viscotoxins, polysaccharides and triterpenoids (including oleanolic
acid, betulinic acid) are then contained in the extract in very high
quantities.
This procedure also allows the formation of mistletoe liposomes (vesicles)
which are formed from the cell membranes occurring naturally in the
plant cell. These structures may be imagined as very small spheres, invisible
to the naked eye, which bind or incorporate the active substances and
other ingredients of mistletoe. Pure mistletoe liposomes have an effect in
their own right: they are immunologically active. This should also be taken
into account in the direct effect of the product on tumour growth.
The good tolerability of these products is also probably due to this.
Using special procedures, manufacturers who use two collection times
mix the extracts with one another and then dilute them appropriately to
the required dose. All the products obtained are then filled in ampoules
following sterile filtration.
Mistletoe products from the Abnoba company are processed under careful
protection from oxidation from the time of collection until sealing of
the ampoules. As a concentrated extract, they have a light yellowishgreen
colour which shows that the liposome-forming and fat-related
membrane substances have been transferred to the aqueous extract. The
high extract yield and the presence of liposomes distinguish these mistletoe
products from other mistletoe products. Greenish or clear preparations
also show that no degradation products resulting from oxidation
have been formed.
The constant quality of the extract is ensured by the specified collection
time, the formula for the plant parts used and the precise organisation
of the manufacturing process as far as this is possible for plant products
at present. Numerous "in-process controls" test the contents of the
extract qualitatively and quantitatively and exclude prohibited impurities.
Manufacture and quality control is performed in accordance with international
standards and the rules of "Good Manufacturing Practice"
(GMP rules) which relate to the current state of knowledge and technology
and are constantly revised in the interests of patient safety.
Mistletoe host trees
Depending on the tree on which a mistletoe plant has grown - the host
tree - the composition of its ingredients can differ. This fact is used therapeutically.
Thus, for example, the high concentration of viscotoxins and
lectins in Viscum album Fraxini can be recommended for the treatment of
metastatic tumour diseases. The Latin word "Fraxini" means "ash" and
designates the tree on which the mistletoe has grown. For Mali (apple
tree) there is good experience, acquired over decades and confirmed by
studies, in the treatment of breast cancer. This applies in the same way to
the oak mistletoe (Quercus), which is used in particular in tumours of the
gastro-intestinal tract, i.e. the digestive tract, and the male sex organs.
The selection of the host tree by your doctor, however, also depends
very substantially on the treatment plan and above all on the individual
disease. In individual cases it may occur that in the treatment of breast
cancer that mistletoe from the pine tree (Pini) or Viscum album Abietis
(fir tree) is used instead of the frequently employed "Mali" species (apple
tree). This is done in order to make the body react in a different way to
the different compositions of the ingredients.
Oak, host tree to oak mistletoe (Viscum album, Quercus)
Where to obtain
support and counselling
You will always find practical social and nursing care and counselling in
your neighbourhood from the welfare institutions. In the telephone
book you will find the addresses of - NHS Direct, 24 hrs a day. Seven days a week please call 0845 4647
www.nhs.direct.nhs.uk
- The Samaritans www.samaritans.org.uk
- Department of Social Security www.dss.gov.uk
- British Red Cross www.redcross.org.uk
These institutions can help you with home nursing, housekeeping and
medical care. Your medical insurance or nursing insurance company is responsible
first and foremost for financing of this assistance.
For more specific questions, such as:
- Which aftercare or rehabilitation clinic is recommended?
- Where can I find a pain clinic in my neighbourhood?
- What financial assistance can a cancer patient claim?
- Who finances domestic help during a period in hospital?
- Who bears the costs for care at home and who for care in a nursing
home
- and whom should I contact in this respect?
and for practical questions about coping with the disease or about the situation
of relatives, you will find the appropriate contacts mentioned below.
Useful addresses
British Red Cross
www.redcross.org.uk
CancerBACUP
3 Bath Place
Rivington Street
London
EC2A 3JR
Tel.02 0 7696 9003
FAX 020 7696 9002
Cancer information helpline (UK only)
0808 800 1234 (freephone)
020 7739 2280 (standard rate)
Tel. 02 28 - 72 99 00
Cancer Research UK
61 Lincoln’s Inn Fields
London, WC2A 3PX
www.cancerresearchuk.org
For specific questions about
Mistletoe therapy please contact
ABNOBA GmbH
E-Mail:
Ash, host tree to ash mistletoe (Viscum album, Fraxini)
Frequently asked questions
When should mistletoe therapy be started?
Therapy can be started before the beginning of what are known as
standard therapies (surgery, chemotherapy and radiotherapy) and is then
intended particularly to improve the tolerability of the standard therapies.
Mistletoe therapy may also possibly be started in the intervals between
cycles of chemotherapy.
In most cases, mistletoe is prescribed after the end of the standard therapies
to prevent recurrences (relapses) and to improve the immune status
and the quality of life.
Mistletoe therapy should always be taken on medical advice and under
medical supervision.
Is there a special diet?
Certain dietary habits make a substantial contribution to health. You
should therefore ensure that wholemeal products, fruit and vegetables
are on the daily menu. The excessive consumption of meat, sugar and fat
should be avoided. Changing your eating habits overnight however
should not cause you to lose your pleasure in eating! Brochures from medical
insurance companies and bookshops offer a rich selection of recommended
diets.
What is the right way to give an injection?
To begin with, your doctor or her/his assistant will show you how to use
the ampoule and the syringe. During the therapy, you yourself or a member
of your family can give the injection. Please note the following:
At the beginning of treatment (for about 8 weeks) when stronger reactions
are possible, the injections should be followed by half an hour's rest.
Change the injection sites. As a rule, injections are given under the abdominal skin and possibly also under the skin on the upper leg.
The area of redness at the injection site, the "local reaction", is much too
large. What does this mean and what can I do differently?
Initially, the local reaction also depends on the angle and the depth beneath
the skin at which you have given the injection. If the injection has
been given at a very shallow angle, a correspondingly large local reaction
may be expected; on the other hand, if the angle of the injection is very
steep, a weaker reaction will be apparent. The diameter of this redness
should be about five centimetres. The local reaction is basically a sign of
a healthy reaction to the medicine. For this reason, an excessive local reaction
is not harmful in terms of an overdose. Obviously, the burning and
itching at the injection site is unpleasant. For this reason, if you have an
excessive reaction, discuss with your doctor whether only half the contents
of the ampoule should be used for the next injection or whether the
dose should be reduced still further.
Storing the ampoules
Active plant substances react sensitively to frequent and excessive temperature
fluctuations. It is therefore recommended that the ampoules
should be stored in a cool, dark place, for instance in the refrigerator.
Before use, however, the ampoules should be brought to room temperature
by warming them briefly in your hands.
Can the contents remaining in the ampoule be used later for other injections?
No, the contents of an opened ampoule can be contaminated with bacteria
and become unsterile, even when handled carefully. In addition, the
drug can oxidise on contact with the oxygen in the air.
I was not able to inject myself on one day. What effects can this have?
As this is a long-term therapy, it is not of major importance. You should
however realise that the stimulus for the immune system to be modulated
is less pronounced as a result.
When should a mistletoe injection not be given?
In general, if the patient has a high fever or if they react allergically to
the injections. The "local reaction" sometimes associated with slight
swelling and itching is not an allergy! If however the itching at the injection
site develops into a generalised itching over the whole body, there
may be an allergy. This very rare reaction should only be described as allergic
if the itching or burning does not disappear with a reduced dose.
Is mistletoe therapy also possible with a malignant disease of the lymphatic
system or the blood?
There have been laboratory tests which suggested that growth of diseased
lymphoma cells would be stimulated by therapy with mistletoe extracts.
This suspicion has not been confirmed either in further cell studies
or in retrospective (i.e. looking back) studies of disease processes. A repeated
laboratory test also contradicts this suspicion. Nevertheless, this
rumour has persisted and has led to uncertainty among patients and doctors,
which is the reason why we are discussing this question here.
No treatment processes are known in which mistletoe has stimulated
the growth of malignant cells. In fact, there are a large number of welldocumented
cases that prove the opposite. The question has also been
studied by a wide range of scientists who also came to the conclusion that
this suspicion is not tenable.
Research by the University of Tübingen commissioned by the Abnoba
company confirms this result.
Can the medicine also be drunk?
No, because mistletoe products lose the effect necessary for cancer
therapy when they come into contact with the mucous membranes of the
mouth and with gastric acid.
What sort of a plant is mistletoe? How is it collected?
There are a variety of species of mistletoe. The mistletoe used for cancer
therapy is the white-berried mistletoe (Viscum album L.), whose main
habitat extends from Europe via Central Asia to Korea and Japan. In
Europe, three subspecies are distinguished within the species of Viscum album: pine, fir and deciduous mistletoe.
Birds like to eat white mistletoe berries in winter and thus ensure the
dispersal of the seeds and thus the plant. The mistletoe seedling attaches
itself to the bark of the host tree and germinates in the spring. It first of
all seeks access to the water-conducting vessels in the tree and instead of
a root drives a so-called sinker through the bark. Over a period of about
4 years, the mistletoe grows - like any normal plant - against gravity, upwards
towards the light. At this stage, the mistletoe is not yet collected.
Only from the 5th year onwards does the typical spherical bush shape appear.
The plant achieves this through oscillating growth movements
which it performs annually in the early summer. Some manufacturers see
this as being the appropriate time for the summer collection. The mistletoe
thus does not just direct its shoots in one direction, but grows actively
in all directions. In winter, the evergreen mistletoe is particularly apparent
as a spherical bush in the middle of the bare trees. When other
plants are resting, mistletoe does not. There is no seed dormancy. The nutrient
tissue of the mistletoe berry which first ripens in winter contains a
green, already germinating embryo with cotyledons (seed leaves) and a
root pole which is attracted to the light shining through the mistletoe
berry. The ripening of the flowering organs is already complete in October.
Flowering in most plants follows rapidly on from this cell division.
The mistletoe takes its time and does not flower until January/February.
Some manufacturers carry out the winter collection at the beginning of
January - at this point the mistletoe berries are ripe and the male and female
flowers not yet open.
Thus, compared to other plants, mistletoe is distinguished by a series of
characteristics which can be described by biological development processes
that are both time-lagged and also spatially independent. These specific
features of mistletoe can also be observed in its spectrum of substances,
which is subject to seasonal variations. For this reason, it is suggested
that a single collection time is not appropriate for the medicinal
product, which involves the whole plant, but that two collection times
are necessary for the production of medicines. For this reason, collection
is performed in summer and winter at predefined collection times identifiable by specific characteristics of biological development.
The mistletoe used for manufacture by the Abnoba company does not
come from crops, but from naturally growing stocks. At each collection
time both the plant and the site are examined, assessed and documented
by experienced biologists. The collected material is processed on the spot
within the first 4 hours of collection. Even in these very early stages of
production, care is taken to ensure that environmental oxygen is excluded
in the processing of the mistletoe. At this stage also measures are taken
to prevent the product later on from containing plant or bacterial degradation
products. Mistletoe leaves, shoots and berries are weighed in
accordance with the predefined formula, divided into portions and stored
in transport containers which prevent any oxidative change in the
collected material until the beginning of drug production.
Before use in
production, the collected material is tested for impurities from pesticides
and heavy metals or infestation with micro-organisms.
Is mistletoe therapy reimbursed by the medical insurance companies?
The use of mistletoe therapy in cancer diseases is permitted by the
National Health Service (NHS) as well as by private insurance companies
(available on prescription on a named patient only).
There are other forms of therapy. What does this mean?
Forms of treatment other than the subcutaneous injection of Viscum
album are mentioned and discussed on the internet and in self-help
groups. These include the following forms of therapy in particular: intravenous
(into the blood circulation), intratumoural (into the tumour or a
metastasis), intrapleural (into the gap in the chest lining) and intravesical
(into the urinary bladder) therapy.
The forms of therapy mentioned are predominantly still in the process
of scientific development and therefore should always only be given by a
doctor and under clinical supervision.
Can mistletoe products be injected together with other medicines?
Mistletoe products should only be injected on their own.
Are there any incompatibilities when taking other medicines at the same
time?
A slight increase in temperature after the injection is desirable at the
beginning of therapy with mistletoe products used in holistic therapy.
These mistletoe preparations should therefore not be taken together
with medicines that lower temperature.
It is essential to seek medical advice if you are taking thymus preparations
during mistletoe therapy.
No incompatibility or interactions with medicines other than those
mentioned is known.
How long does mistletoe therapy last? Can breaks be introduced into longterm
therapy?
Depending on the risk of relapse of the tumour concerned and/or the
required stimulus for immunomodulation, mistletoe therapy will continue
for a period of a few months to several years. Injections are given
more often at the beginning of therapy and subsequently often only
once or twice a week and breaks can be introduced into the treatment.
Following a break of more than two months, the treatment should be
started again at a low dose (as at the beginning of therapy), and at all
events under medical supervision.
Mistletoe branch in winter
Medical and
pharmaceutical terms
Adenokarzinom
a cancer arising from the glandular parts of the mucous
membrane.
Adjuvant
accompanying, in the sense of accompanying and supportive
therapy.
Allergy
hereditary or acquired, hypersensitive reaction of the body’s immune
system to foreign substances.
Apoptosis
describes the process programmed naturally into all healthy
cells, resulting in the death of diseased or "obsolete" cells. This process
is also induced in diseased cells by lectins.
Axillary
belonging to or situated in the armpit (axilla)
B-cells
see lymphocytes
Biopsy
removal of tissue samples. In the context of a tumour disease,
tissue is removed to determine the nature of the tumour.
Carcinoma
a cancer
Carcinoma in situ
initial tumour stage in which the tumour has not yet
invaded the surrounding tissue and has no connection to the blood circulation.
Circadian
daily 24-hour rhythm
Colon
belonging to the large bowel
Colon carcinoma
cancer in the large bowel
Complementary
supplementing
Cytokines
proteins which are released, among others, by cells of the
immune system and serve as "information" between cells, tissues and organs.
Cytostatic
a medicine which is intended to stop uncontrolled cell growth.
Cytotoxic
a poison which damages a cell so much that it dies (see also
apoptosis and necrosis).
Dysplasia
pathological change in a tissue
Endocrine therapy
hormonal therapy
Endorphins
pain-blocking substances within the body
Epithelium
uppermost or outermost tissue of an organ or internal and
external body surface, e.g. of the skin or the inner wall of the bladder.
Gliomas
tumours of the supporting tissue of the nervous system known
as glia.
Grading
assessment of tumour tissue according to the degree of malignancy.
G1 means: well differentiated, the tumour tissue is still largely
the same as the tissue from which it is growing; G2: moderately differentiated;
G3: poorly differentiated; and Gx: an exact classification is
not possible. A tumour defined as G1 may be considered less malignant
than one defined as G2 (see also keyword: TNM)
Granulocytes
various subgroups of these cells belonging to the white
blood corpuscles digest bacteria, fungi and in particular the "waste"
from tissue destroyed by inflammation, as a result of which the susceptibility
to infections is reduced.
Haematology
field of internal medicine which deals with the causes
and therapy of blood diseases.
Histology
study of the body’s tissues
Hodgkin’s disease
is a specific group of diseases of the lymphatic system
which usually initially develop locally in a lymph node (see also lymph
nodes and lymphatic system).
Hormonal therapy
see page 22
Host tree
tree on which a mistletoe grows. The Latin names are for example:
Abietis (fir), Aceris (maple), Amygdali (almond), Betulae (birch),
Crataegi (whitethorn), Fraxini (ash), Mali (apple), Pini (pine), Quercus
(oak).
Immune system
individual system for fighting off foreign substances and destroying abnormal cells. A distinction is made between inherited
and acquired, e.g. learnt by taking drugs, immune defence.
Infiltrate
to invade surrounding tissue
Infiltration
Infiltration is the process by which a tumour invades surrounding
tissue.
Inject
to administer a substance using a needle
Instillation
Instillation describes the introduction of medicines into the
body cavities of the human body (e.g. bladder).
Invasive
see infiltration above
Lectins
lectins are medicinal substances contained in mistletoe which
cause apoptosis in particular.
Leucocytes
so-called "white blood corpuscles", see also granulocytes
and lymphocytes.
Leukaemia
tumour disease of the blood-forming organs or of the
blood.
Liposomes
see page 32/33
Lokalreaktion
at the injection site, the skin often reacts in the form of
redness and swelling. This reaction to an injection, which is also accompanied
by itching, appears about seven hours after the injection
and lasts for up to three days.
Lymph nodes
organ of the lymphatic system (see below) which in particular
purifies lymph fluids and, stimulated by messenger substances
from the bone marrow, releases lymphocytes among others.
Lymphatic system
the lymphatic system consists in particular of lymph
tracts, lymph nodes, the spleen, the bone marrow and sections of the
intestine; in children it also includes the thymus, but this regresses during
puberty. Lymph tracts and nodes are distributed throughout the
whole body and collect the lymph fluid produced from the tissue,
which is returned to the blood in the neighbourhood of the heart. The
lymphocytes (see there), which are important for the immune system
and the production of which is stimulated in the bone marrow or
thymus, are also transported with the lymph. However, dietary fat also
reaches the blood from the intestine via the lymphatic system.
Lymphocytes
belonging to the group of "white blood corpuscles", lymphocytes
are cells in the blood which are "produced" by the spleen and
the lymph nodes. These organs in turn are stimulated by cells from the
bone marrow to form lymphocytes. The lymphocytes comprise:
- B-lymphocytes
- these perform "recognition and memory functions"
for fighting foreign substances.
- T-lymphocytes
- "fight" these substances or foreign cells directly.
- Natural killer cells
- these cells also "fight" foreign substances and
cells. They perform this activity by virtue of their naturally assigned
function (non-specific immunity).
Lymphomas
are, if described as malignant, a cancer disease of the lymphatic
system. The unbalanced overproduction of malignant cells results
in disease.
Macrophages
("scavenger cells"), mobile and locally based cells in the
immune system which have predominantly cleaning functions but
which also stimulate other cells to perform their respective functions
(e.g. by releasing interleukins).
Maintenance therapy
is the treatment that follows on from the initial
therapy. This therapy is usually followed at an unchanged dosage over
several years.
Malignant dysplasia
pathological change of the tissue; preliminary
stage of cancer
Malignoma
malignant, independent tumours with uncontrolled growth,
in contrast to benign tumours, such as warts or polyps.
Mammary carcinoma
breast cancer
Metastasis
secondary growth of a tumour which is found elsewhere in
the body from the original tumour.
Natural killer cells
see lymphocytes
Necrosis
in contrast to apoptosis (see there), natural cell death, necrosis
describes the death of the cell caused by an external influence, often
accompanied by inflammation. The viscotoxins contained in mistletoe
can cause this form of cell death. Mistletoe harvested in summer in particular contains viscotoxins.
Neoadjuvant
the term used for a therapy used before another therapy,
e.g. before surgery.
NK cells
see lymphocytes
Oncogenes
tumour-producing genes
Oncology
field of internal medicine dealing with the origin and therapy
of cancer diseases.
Oxidation
chemical change/production of a substance by oxygen
among others, e.g. rust formation on iron
Palliative
Latin for “cloaking“, palliative therapy = alleviating therapy
Pancreas
a gland that secretes a gastric juice
Phytopharmaca
medicinal products obtained from plants.
Pleura
(Latin for chest lining) two-layered tissue closely enveloping the
lung. During a cancer disease, fluid can accumulate between these layers.
This accumulation is known as pleural effusion.
Process standardisation
term used in pharmaceutical production which
describes a system of quality assurance measures that result ultimately
in a defined and constant drug quality.
Prophylaxis
preventive measure
Psychosomatic
interaction between mental and physical health.
Radiotherapy
see page 18
Reconvalescence
recovery phase after a disease or severe stress
Relapse prophylaxis
preventive therapy to avoid relapses
Relapse/Local relapse
recurrence of a tumour at the place in the body
from which it was previously removed.
Sarcoma
malignant tumour affecting the connective and supporting
tissue.
Side-effects of mistletoe injection
see pages 28/29
Spontaneous cure
spontaneous remission = rare but constantly recurring,
complete cure of the cancer disease without any explanation.
Subcutaneous, abbreviated sc.
Latin for "under the skin", meaning the
injection of a medicine under the skin.
T-cells
see lymphocytes
Therapeutic eurhythmy
a movement therapy which stimulates in particular
the ordering immune and life forces.
TNM system, TNM classification
this internationally used classification
is used to describe a tumour:
- TX:
- The tumour (=T) cannot be assessed.
- Tis:
- Carcinoma in situ = initial tumour stage without invasive formation
in surrounding tissue.
- T0:
- No evidence of primary tumour
- T1, 2, 3, 4:
- size and spread of the tumour (1 = small, 4 = large)
- NX:
- The involvement of regional lymph nodes (i.e. in the area of the
tumour) cannot be assessed.
- N0:
- No evidence of regional lymph node involvement.
- N1, 2, 3, 4:
- 2, 3, 4: Weak (= 1) or marked (= 4) lymph node involvement.
- MX:
- Distant metastases cannot be assessed.
- M0:
- Distant metastases are not detectable.
- M1:
- Distant metastases are detectable.
A "T1,N0,M0" classification is thus associated with a good therapeutic
prognosis
Tumour markers
Blood constituents which can reveal the presence of
a cancer disease.
Viscotoxins
= group of substances of cytotoxic ingredients of the mistletoe
extract which can in particular cause necrosis (see there) of tumour
cells.
Viscum
Latin name for “mistletoe“.
Dear reader
Obviously, this brochure does not claim to be a scientific publication.
What it intends to do instead is to provide an informative, factual overview
of the purpose and practice of mistletoe therapy in cancer disease
and, at the same time, to show its relationship with standard therapies.
Thank you for your interest, please send your criticisms and suggestions
for improvement to us! And naturally we would also be happy to receive
any positive feedback.
With best wishes and kind regards
The staff at
ABNOBA Heilmittel GmbH
Almond blossom, almond tree, host tree to almond mistletoe (Viscum album, Amygdali)